Alpha 2.0
Login Register
» Authors » Emma C de Moel

Emma C de Moel

Explore the profile of Emma C de Moel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 179
Followers 0
Related Specialties
Rheumatology
Oncology
Allergy & Immunology
Top 10 Co-Authors
Tom W J Huizinga
Diane van der Woude
Rene E M Toes
Cornelia F Allaart
Leendert A Trouw
Holger Bang
Veerle F A M Derksen
Robbert J Goekoop
Thomas Vogl
John B Haanen
Published In
Arthritis Res Ther
Ann Rheum Dis
Arthritis Rheumatol
Cancer Immunol Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations
de Moel E, Trouw L, Terao C, Govind N, Tikly M, El-Gabalawy H, et al.
Arthritis Res Ther . 2023 Mar; 25(1):37. PMID: 36890568
Background: Rheumatoid arthritis (RA) occurs across the globe in different ethnic populations. Most RA patients harbor anti-modified protein antibodies (AMPA); however, it is unclear whether differences exist in autoantibody responses...
2.
Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
Amkreutz J, de Moel E, Theander L, Willim M, Heimans L, Nilsson J, et al.
Arthritis Rheumatol . 2020 Dec; 73(6):921-930. PMID: 33314699
Objective: Autoantibodies, such as anti-citrullinated protein antibodies (ACPAs), have been described as inducing bone loss in rheumatoid arthritis (RA), which can also be reflected by bone mineral density (BMD). We...
3.
Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
de Moel E, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A, et al.
Arthritis Res Ther . 2019 Dec; 21(1):268. PMID: 31805992
Objective: To investigate whether calprotectin (S100A8/A9 or MRP8/14), an inflammatory complex released by monocytes, could indicate residual subclinical inflammation in rheumatoid arthritis (RA) patients who are in stable remission on...
4.
In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
de Moel E, Derksen V, Trouw L, Bang H, Collee G, Lard L, et al.
Arthritis Res Ther . 2019 Jan; 21(1):28. PMID: 30658699
Background: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), and anti-carbamylated protein (anti-CarP) antibodies. It is currently unclear whether changes...
5.
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
de Moel E, Rozeman E, Kapiteijn E, Verdegaal E, Grummels A, Bakker J, et al.
Cancer Immunol Res . 2018 Nov; 7(1):6-11. PMID: 30425107
Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting...
6.
In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission
de Moel E, Derksen V, Trouw L, Bang H, Goekoop-Ruiterman Y, Steup-Beekman G, et al.
Ann Rheum Dis . 2018 Jul; 77(12):1836-1838. PMID: 30045852
No abstract available.
7.
Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes
de Moel E, Derksen V, Stoeken G, Trouw L, Bang H, Goekoop R, et al.
Arthritis Res Ther . 2018 Feb; 20(1):33. PMID: 29482627
Background: The autoantibody profile of seropositive rheumatoid arthritis (RA) is very diverse and consists of various isotypes and antibodies to multiple post-translational modifications. It is yet unknown whether this varying...
8.
Is optimising gout treatment the key to closing the mortality gap in gout patients?
Ten Brinck R, de Moel E, van der Pol J, van Beest S, de Koning A, Huizinga T
Ann Rheum Dis . 2017 May; 77(1):e2. PMID: 28546256
No abstract available.